Wold E, Smider V, Felding B
Immunotherapy (Los Angel). 2016; 2(1).
PMID: 27081677
PMC: 4829403.
Gorantla V, Kirkwood J
Hematol Oncol Clin North Am. 2014; 28(3):415-35.
PMID: 24880939
PMC: 4040458.
DOI: 10.1016/j.hoc.2014.02.010.
Barker C, Postow M
Int J Radiat Oncol Biol Phys. 2014; 88(5):986-97.
PMID: 24661650
PMC: 4667362.
DOI: 10.1016/j.ijrobp.2013.08.035.
Madorsky-Rowdo F, Lacreu M, Mordoh J
Front Immunol. 2012; 3:103.
PMID: 22566975
PMC: 3343264.
DOI: 10.3389/fimmu.2012.00103.
Hellstrom I, Hellstrom K
Expert Opin Med Diagn. 2011; 5(3):227-240.
PMID: 21643459
PMC: 3107036.
DOI: 10.1517/17530059.2011.559459.
Usage of cancer associated autoantibodies in the detection of disease.
Dudas S, Chatterjee M, Tainsky M
Cancer Biomark. 2010; 6(5-6):257-70.
PMID: 20938086
PMC: 3791486.
DOI: 10.3233/CBM-2009-0138.
Therapeutic vaccination with tumor cells that engage CD137.
Hellstrom K, Hellstrom I
J Mol Med (Berl). 2003; 81(2):71-86.
PMID: 12601523
DOI: 10.1007/s00109-002-0413-8.
Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.
Morton D, Hsueh E, Essner R, Foshag L, ODay S, Bilchik A
Ann Surg. 2002; 236(4):438-48; discussion 448-9.
PMID: 12368672
PMC: 1422598.
DOI: 10.1097/00000658-200210000-00006.
Regulation of CR3 (CD11b/CD18)-dependent natural killer (NK) cell cytotoxicity by tumour target cell MHC class I molecules.
Vetvicka V, Hanikyrova M, Vetvickova J, Ross G
Clin Exp Immunol. 1999; 115(2):229-35.
PMID: 9933447
PMC: 1905157.
DOI: 10.1046/j.1365-2249.1999.00800.x.
Monoclonal antibody-directed effector cells selectively lyse human melanoma cells in vitro and in vivo.
Schulz G, Bumol T, Reisfeld R
Proc Natl Acad Sci U S A. 1983; 80(17):5407-11.
PMID: 6577434
PMC: 384265.
DOI: 10.1073/pnas.80.17.5407.
Inhibition of the arrest of hematogenously disseminated tumor cells.
Tsubura E, Yamashita T, Sone S
Cancer Metastasis Rev. 1983; 2(3):223-37.
PMID: 6367967
DOI: 10.1007/BF00048479.
Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
SILVER H, Ibrahim E, EVERS J, Thomas J, Murray R, Spinelli J
Can Med Assoc J. 1983; 128(11):1291-5.
PMID: 6342739
PMC: 1874918.
Lymphoma-associated antigen (LAA): isolation, characterization and clinical evaluation.
UDAYACHANDER M, Meenakshi A, Ansamma J, Muthiah R
Br J Cancer. 1983; 48(5):717-25.
PMID: 6315041
PMC: 2011531.
DOI: 10.1038/bjc.1983.255.
Immunochemical delineation of an oncofetal antigen on normal and simian virus 40-transformed human fetal melanocytes.
Morgan Jr A, Galloway D, JENSEN F, GIOVANELLA B, Reisfeld R
Proc Natl Acad Sci U S A. 1981; 78(6):3834-8.
PMID: 6267607
PMC: 319667.
DOI: 10.1073/pnas.78.6.3834.
Detection of tumour associated antigen in eluates from protein A columns used for ex vivo immunoadsorption of plasma from melanoma patients by radioimmunoassay.
Gupta R, Leitch A, Morton D
Clin Exp Immunol. 1983; 53(3):589-99.
PMID: 6193912
PMC: 1535629.
Human tumor-associated antigens identified by monoclonal antibodies.
Hellstrom K, Hellstrom I, Brown J
Springer Semin Immunopathol. 1982; 5(2):127-46.
PMID: 6183764
DOI: 10.1007/BF00199792.
[Monoclonal antibodies against surface antigens of laryngeal carcinoma cells (author's transl)].
Zenner H
Arch Otorhinolaryngol. 1981; 233(2):161-72.
PMID: 6172103
DOI: 10.1007/BF00453640.
Further characterization of a melanoma-specific protein from human urine.
Bennett C, COOKE K
Br J Cancer. 1980; 41(5):734-44.
PMID: 6158965
PMC: 2010305.
DOI: 10.1038/bjc.1980.135.
Antigens in human sarcomas and melanomas.
Br Med J. 1969; 3(5670):543.
PMID: 5803681
PMC: 1984327.
DOI: 10.1136/bmj.3.5670.543.
Immunity to malignant disease in man.
Fairley G
Br Med J. 1969; 2(5655):467-73.
PMID: 5771576
PMC: 1983396.
DOI: 10.1136/bmj.2.5655.467.
